The U.S. Food and Drug Administration (FDA) is raising concerns about the cybersecurity, artificial intelligence (AI), and patient safety risks associated with emerging autonomous and remotely operated medical robots.

 

What happened

In a November 10, 2026, BankInfoSecurity report, Marianne Kolbasuk McGee reported that the FDA is seeking public feedback on the potential risks and benefits of robotic medical devices that can perform procedures autonomously or be controlled remotely by healthcare professionals.

The FDA's Center for Devices and Radiological Health (CDRH) released a discussion paper titled Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities. The paper examines how these technologies could affect patient safety, clinical outcomes, and healthcare delivery, while identifying potential cybersecurity vulnerabilities.

The FDA is particularly concerned that cybersecurity incidents could compromise a robot's ability to make decisions, communicate with healthcare professionals, or safely perform medical procedures. The agency is inviting medical device manufacturers, healthcare providers, patients, and other stakeholders to submit feedback by January 5, 2027, under docket number FDA-2026-N-13135.

The FDA emphasized that the discussion paper is intended to encourage early engagement and does not represent draft or final regulatory guidance.

 

Going deeper

Cybersecurity vulnerabilities could directly affect patient safety

The increasing connectivity of medical robots introduces additional cybersecurity risks. These devices may rely on networks, sensors, imaging systems, and remote communication technologies to perform procedures and receive instructions.

According to the FDA, a cybersecurity breach could compromise the functionality, availability, and integrity of a robotic medical device. Attackers could potentially interfere with the commands sent to a device, disrupt network connectivity, or manipulate information used to guide medical procedures. The risks become more significant when a device combines autonomous capabilities with remote operation. A cybersecurity incident could simultaneously affect the robot's independent decision-making and the healthcare professional's ability to control it remotely.

The FDA also indicated the possibility of compromised video feeds. For example, a healthcare professional operating a robot remotely may not recognize that the visual information being transmitted has been manipulated, potentially affecting clinical decisions.

 

AI introduces additional risks to autonomous medical devices

The FDA also raised concerns about AI and machine learning (ML) systems used to support autonomous medical procedures. Unlike conventional automated systems that follow predefined instructions, AI-powered devices may use algorithms to interpret information and make decisions based on changing clinical conditions. However, these systems may not always perform as expected when encountering situations outside their training data.

The FDA identified several potential concerns, including:

  • Unpredictable performance: AI-powered systems may respond incorrectly to clinical situations that were not sufficiently represented in their training data.
  • Algorithmic bias: AI performance may differ across patient populations, particularly when training datasets do not adequately represent the intended patient population.
  • Limited transparency: Healthcare professionals may struggle to understand how an AI system reached a particular decision, making it more difficult to evaluate or override its actions.
  • Performance degradation: Changes in clinical environments, patient populations, or device configurations could affect an algorithm's performance over time.

 

Remote operation creates additional clinical and technical challenges

Remote teleoperation allows healthcare professionals to control robotic medical devices without being physically present with the patient. Although this could improve access to specialized healthcare, particularly in underserved areas, it introduces risks associated with network connectivity, communication delays, and limited sensory feedback.

For example, a loss of connectivity during a procedure could prevent a healthcare professional from responding to an emergency. Similarly, network latency could delay commands sent to a robotic device, potentially affecting the timing and accuracy of medical interventions.

The FDA also highlighted the challenges of managing complications when the healthcare professional operating the device is not physically present in the room.

The agency is therefore examining how manufacturers can ensure that these devices remain safe and functional when connectivity is disrupted or unexpected complications occur.

 

What was said

In its discussion paper, the FDA highlighted the potential consequences of cybersecurity vulnerabilities in connected robotic medical devices. The agency stated, “A cybersecurity threat could compromise the robotic device system’s functionality, availability, data integrity, or the security of connected networks, with direct implications for patient safety.”

The FDA also addressed the limitations of AI-powered autonomous systems, particularly when they encounter clinical situations outside their training data. The agency explained that “AI/ML-based autonomous systems may perform unpredictably when encountering intraprocedural conditions outside the scope of their training data.”

Regarding the potential benefits of these technologies, the FDA acknowledged that autonomous and remotely operated medical robots could improve access to specialized healthcare and support more consistent medical procedures.

However, it emphasized that evaluating the risks associated with different levels of autonomy and remote operation remains important.

The agency stated that its discussion paper is intended to promote early engagement with stakeholders and advance a broader discussion about the safe use of these technologies. It also clarified that the document does not establish new regulatory requirements or communicate proposed regulatory expectations.

 

Why it matters

Cybersecurity incidents could have consequences from AI-powered and connected medical devices beyond data breaches, potentially putting patient safety and clinical outcomes at risk. Manufacturers and healthcare providers must prioritize device security, human oversight, and contingency plans to ensure that robotic systems remain safe and functional during cyber incidents or technical failures.

See also: HIPAA Compliant Email: The Definitive Guide (2026 Update)

 

FAQS

What are autonomous medical robots?

Autonomous medical robots are robotic systems that use software, sensors, and, in some cases, AI to perform or assist with medical procedures with varying levels of independence from human operators.

 

How can healthcare organizations protect robotic medical devices?

Healthcare organizations should implement network security controls, restrict access to device systems, monitor connected devices, and maintain incident response plans. They should also ensure that healthcare professionals can manually intervene when a device malfunctions.

 

Why is human oversight important in autonomous medical procedures?

Human oversight allows healthcare professionals to identify errors, assess unexpected clinical situations, and intervene when an AI-powered system makes an incorrect decision. Reliable manual controls are particularly important when autonomous systems encounter situations they were not designed to handle.